Stockscreener 앱 받기
1.38
0.00%
0.00
시간 외 거래:
1.38
전일 마감가:
$1.38
열려 있는:
$1.44
하루 거래량:
26,971
Relative Volume:
0.76
시가총액:
$8.49M
수익:
$93.76M
순이익/손실:
$-13.68M
주가수익비율:
-0.1344
EPS:
-10.27
순현금흐름:
$8.77M
1주 성능:
-4.17%
1개월 성능:
-7.38%
6개월 성능:
-50.71%
1년 성능:
-51.75%
1일 변동 폭
$1.35
$1.44
1주일 범위
$1.3001
$1.47
52주 변동 폭
$1.3001
$3.45
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
AYTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.38 | 8.49M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance
Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan
Aytu BioPharma Disclosure Notification - AccessWire
Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance
Aytu Biopharma Inc (AYTU-Q) QuotePress Release - The Globe and Mail
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - AccessWire
Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan
Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com
Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St
Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks
Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch
Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan
Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500
Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia
Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa
AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com South Africa
Earnings call: Aytu BioPharma reports turnaround with focus on ADHD - Investing.com
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
1.65%
자본화:
|
볼륨(24시간):